Spin-offs can bring some serious added value to a company. The idea that the individual parts of a company are worth more than when they're combined may sound counterintuitive to some, but it can actually be true.
Witness the old Abraxis BioScience -- half biotech one-drug wonder, half generic-drug maker. When the company broke apart last November, investors were valuing the centaur of the drug world at just $3.5 billion. Now, the two separate companies, APP Pharmaceuticals (Nasdaq: APPX) and Abraxis BioScience (Nasdaq: ABII), are together worth more than $6 billion. I'd call that a successful spin-off.
But part of that value comes from German company Fresenius and its announcement yesterday of plans to purchase APP Pharmaceuticals for $23 per share -- a 29% premium over the previous closing price. (Before the announcement, the duo was worth about $5.3 billion -- still successful.)
Investors in the purchased generic-drug company could see even more money headed their way. APP Pharmaceuticals will remain a stand-alone company, and if certain targets are met, investors will be entitled to up to an additional $6 per share payable in the second quarter of 2011.
The synergies between APP Pharmaceuticals and Fresenius are pretty good, too. The merger will allow APP Pharmaceuticals to sell its generic-injectable drugs globally without huge start-up costs, and Fresenius gets a foot in the lucrative U.S. generic-drug market. Not a bad deal.
With foreign drug companies snatching up their American counterparts, it's fun to speculate which stateside generic-drug companies might be next. Hospira (NYSE: HSP), a 2004 spin-off of Abbott Labs (NYSE: ABT), might be a takeover target, as could small generic-drug companies like Watson Pharmaceuticals (NYSE: WPI) or Par Pharmaceutical (NYSE: PRX).
The potential for takeover isn't a reason to invest in these companies, but, as APP Pharmaceuticals' investors have found out, it sure is a nice added bonus.
More Foolishness on foreign drug companies coming stateside:
“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.
Terms & Conditions
RSS Headlines
Fool UK